General Information of Drug (ID: DMT1GJL)

Drug Name
SC-560 Drug Info
Synonyms
SC-560; 188817-13-2; SC 560; 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole; razole; SC560; 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole; CHEMBL26915; CHEBI:76274; 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole; 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole; Lopac-S-2064; AC1N7Q9I; Lopac0_001086; SCHEMBL676921; GTPL10240; CTK8E8897; BDBM13065; DTXSID00401775; QCR-133; MolPort-003-959-517; HMS3268E05; ZINC2391787; BCP07005; EX-A1507; CS-006
Cross-matching ID
PubChem CID
4306515
ChEBI ID
CHEMBL26915
CAS Number
CAS 188817-13-2
TTD Drug ID
D0M5MI

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
Protein digestion and absorption 1.86 2.01e-1 78/103 (75.73%) COL14A1;COL6A1;COL1A2;...
Glycolysis / Gluconeogenesis 1.77 2.01e-1 56/67 (83.58%) GPI;PCK2;HK2;...
Tyrosine metabolism 1.76 1.42e-1 30/36 (83.33%) TYRP1;ADH5;DDC;...
Th1 and Th2 cell differentiation 1.75 1.26e-1 80/92 (86.96%) IL2RG;HLA-DRA;HLA-DPA1;...
Valine, leucine and isoleucine degradation 1.72 1.31e-1 42/48 (87.5%) HMGCS2;MCCC2;ALDH2;...
Glycine, serine and threonine metabolism 1.71 1.21e-1 31/40 (77.5%) PSAT1;GATM;PGAM1;...
Phototransduction 1.67 1.34e-1 21/29 (72.41%) CALML3;CALML5;CALML4
One carbon pool by folate 1.64 1.63e-1 15/20 (75%) SHMT2;MTHFD2;ALDH1L1;...
Intestinal immune network for IgA production 1.64 1.46e-1 38/48 (79.17%) CXCL12;HLA-DRA;HLA-DPA1;...
Inflammatory mediator regulation of TRP channels 1.59 1.95e-1 82/98 (83.67%) CALML3;IGF1;MAP2K6;...
Inflammatory bowel disease 1.59 1.77e-1 58/65 (89.23%) IL2RG;HLA-DRA;HLA-DPA1;...
Graft-versus-host disease 1.58 1.74e-1 32/42 (76.19%) HLA-DRA;HLA-DPA1;HLA-DPB1;...
Starch and sucrose metabolism 1.57 1.69e-1 25/36 (69.44%) GPI;HK2;GAA;...
Fructose and mannose metabolism 1.57 1.67e-1 30/33 (90.91%) SORD;HK2;PFKL;...
Th17 cell differentiation 1.55 1.77e-1 95/107 (88.79%) IL2RG;HLA-DRA;HLA-DPA1;...
Asthma 1.53 1.98e-1 25/31 (80.65%) HLA-DRA;HLA-DPA1;HLA-DPB1;...
Glyoxylate and dicarboxylate metabolism 1.53 1.86e-1 23/30 (76.67%) SHMT2;DLD;ACO2;...
Cell adhesion molecules 1.51 2.13e-1 118/148 (79.73%) VCAM1;SDC1;HLA-DRA;...
Pentose and glucuronate interconversions 1.50 2.11e-1 17/34 (50%) SORD;UGT2B28;CRYL1;...
Viral protein interaction with cytokine and cytokine re... 1.50 2.08e-1 84/100 (84%) CXCL12;CXCL14;IL2RG;...
Diabetic cardiomyopathy 1.46 2.89e-1 162/203 (79.8%) COL1A2;ATP2A3;COL3A1;...
Allograft rejection 1.43 3.38e-1 32/38 (84.21%) HLA-DRA;HLA-DPA1;HLA-DPB1;...
Type I diabetes mellitus 1.43 3.25e-1 38/43 (88.37%) HLA-DRA;HLA-DPA1;HLA-DPB1;...
ECM-receptor interaction 1.42 3.25e-1 80/88 (90.91%) COL6A1;COL1A2;SDC1;...
Systemic lupus erythematosus 1.40 3.75e-1 45/135 (33.33%) HLA-DRA;C1R;ELANE;...
Homologous recombination 1.39 3.83e-1 35/41 (85.37%) BRIP1;NBN;RAD54B;...
Progesterone-mediated oocyte maturation 1.38 3.81e-1 75/100 (75%) GNAI1;IGF1;AKT3;...
Fatty acid degradation 1.35 4.51e-1 40/43 (93.02%) ADH5;ALDH2;ACSL5;...
DNA replication 1.33 4.61e-1 34/36 (94.44%) PRIM1;POLA1;LIG1;...
Alcoholism 1.33 4.49e-1 86/186 (46.24%) CALML3;NTRK2;GNAI1;...
Regulation of actin cytoskeleton -1.14 7.31e-1 185/218 (84.86%) ARHGAP35;ARPC2;FGF7;...
Thyroid hormone synthesis -1.18 6.94e-1 66/75 (88%) SLC26A4;TSHB;DUOX1;...
Glycerophospholipid metabolism -1.19 6.99e-1 71/98 (72.45%) PLA2G15;DGKG;LPCAT3;...
Shigellosis -1.21 6.39e-1 180/246 (73.17%) FOXO4;ITPR2;ACTR3;...
Viral myocarditis -1.23 5.54e-1 53/60 (88.33%) MYH7;CD86;CASP9;...
Endocytosis -1.25 5.22e-1 198/252 (78.57%) PARD3;ITCH;CLTC;...
Mineral absorption -1.25 5.33e-1 48/60 (80%) TF;ATP1B2;SLC11A2;...
Ferroptosis -1.27 4.84e-1 36/41 (87.8%) GCLC;TF;PRNP;...
Mucin type O-glycan biosynthesis -1.28 4.84e-1 20/36 (55.56%) ST3GAL1;GALNT3;GCNT1;...
Amoebiasis -1.28 4.98e-1 99/102 (97.06%) GNA15;CD1E;COL4A1;...
Focal adhesion -1.28 5.20e-1 180/201 (89.55%) ARHGAP35;RAP1B;ACTN4;...
Riboflavin metabolism -1.31 4.52e-1 7/8 (87.5%) ACP5;ACP2;RFK;...
Mitophagy -1.33 4.32e-1 56/68 (82.35%) TFEB;MFN2;ATG5;...
Autophagy -1.34 4.11e-1 113/169 (66.86%) RAF1;ATG5;PIK3CA;...
Tight junction -1.34 4.30e-1 130/169 (76.92%) PRKAG1;SYNPO;PARD6A;...
Ubiquinone and other terpenoid-quinone biosynthesis -1.35 4.41e-1 9/11 (81.82%) COQ2;COQ6;NQO1;...
Sphingolipid metabolism -1.38 4.01e-1 32/49 (65.31%) CERS6;SGPL1;NEU3;...
Salmonella infection -1.42 3.10e-1 198/249 (79.52%) TAB1;NFKBIA;TCF7L2;...
Legionellosis -1.44 3.05e-1 51/57 (89.47%) NFKBIA;ITGAM;TNF;...
Arachidonic acid metabolism -1.45 3.03e-1 48/61 (78.69%) CYP2E1;PLA2G5;PLA2G12A;...
Phagosome -1.45 3.27e-1 118/152 (77.63%) PIKFYVE;CD36;TCIRG1;...
Maturity onset diabetes of the young -1.46 3.33e-1 21/26 (80.77%) NKX2-2;GCK;NEUROD1;...
Ether lipid metabolism -1.47 3.59e-1 32/49 (65.31%) PLA2G5;AGPS;PLA2G12A;...
Pathogenic Escherichia coli infection -1.50 3.01e-1 152/197 (77.16%) ARPC2;NCK1;NCKAP1L;...
Cholesterol metabolism -1.53 2.79e-1 44/50 (88%) LPL;APOC1;CD36;...
Lysosome -1.57 2.11e-1 115/128 (89.84%) CLTA;DNASE2;ACP5;...
Bacterial invasion of epithelial cells -1.61 1.71e-1 59/77 (76.62%) ARPC3;ARPC2;CLTA;...
Steroid biosynthesis -1.64 1.55e-1 19/20 (95%) CYP51A1;SOAT1;MSMO1;...
alpha-Linolenic acid metabolism -1.68 1.56e-1 17/25 (68%) FADS2;PLA2G5;PLA2G12A;...
Linoleic acid metabolism -1.70 2.62e-1 21/29 (72.41%) CYP2E1;PLA2G5;PLA2G12A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 3.33uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H